BR112014007247A2 - alisporivir para o tratamento de infecção por vírus da hepatite c - Google Patents

alisporivir para o tratamento de infecção por vírus da hepatite c

Info

Publication number
BR112014007247A2
BR112014007247A2 BR112014007247A BR112014007247A BR112014007247A2 BR 112014007247 A2 BR112014007247 A2 BR 112014007247A2 BR 112014007247 A BR112014007247 A BR 112014007247A BR 112014007247 A BR112014007247 A BR 112014007247A BR 112014007247 A2 BR112014007247 A2 BR 112014007247A2
Authority
BR
Brazil
Prior art keywords
alisporivir
hepatitis
treatment
weeks
administered
Prior art date
Application number
BR112014007247A
Other languages
English (en)
Inventor
Avila Claudio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014007247A2 publication Critical patent/BR112014007247A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

resumo patente de invenção: "alisporivir para o tratamento de infecção por vírus da hepatite c". a presente invenção refere-se ao uso de alisporivir (= debio-025 ou deb025) no tratamento de paciente afro-americano infectado com infecção por vírus de hepatite c genótipo 1. o alisporivir será administrado em uma quantidade de aproximadamente 400 a aproximadamente 600 mg duas vezes ao dia, preferencialmente em combinação com outros agentes antivirais. em uma modalidade preferencial, o seguinte regime de dosagem é administrado: interferon alfa 2a peguilado (pegasys) em uma dose de 180 ug subcutaneamente uma vez por semana por 24 ou 48 semanas em combinação com ribavirina (rbv ou copegus) administrado em uma dosagem oral de 800/1200 mg ao dia (baseado em peso) por 24 ou 48 semanas e 400 mg de alisporivir (deb025) oralmente duas vezes ao dia por 24 ou 48 semanas.
BR112014007247A 2011-09-27 2012-09-25 alisporivir para o tratamento de infecção por vírus da hepatite c BR112014007247A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539662P 2011-09-27 2011-09-27
PCT/EP2012/068896 WO2013045460A1 (en) 2011-09-27 2012-09-25 Alisporivr for treatment of hepatis c virus infection

Publications (1)

Publication Number Publication Date
BR112014007247A2 true BR112014007247A2 (pt) 2017-03-28

Family

ID=46924444

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014007247A BR112014007247A2 (pt) 2011-09-27 2012-09-25 alisporivir para o tratamento de infecção por vírus da hepatite c

Country Status (11)

Country Link
US (2) US20140228281A1 (pt)
EP (1) EP2760461A1 (pt)
JP (1) JP2014528947A (pt)
KR (1) KR20140070565A (pt)
CN (1) CN103826654A (pt)
AU (1) AU2012314517A1 (pt)
BR (1) BR112014007247A2 (pt)
CA (1) CA2850052A1 (pt)
MX (1) MX2014003753A (pt)
RU (1) RU2014116988A (pt)
WO (1) WO2013045460A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015136455A1 (en) * 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0730470B1 (en) 1993-11-10 2002-03-27 Enzon, Inc. Improved interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
UA88484C2 (ru) 2004-10-01 2009-10-26 Дебиофарм Са ПРИМЕНЕНИЕ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ВКЛЮЧАЕТ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИН
MX2007007779A (es) 2004-12-23 2007-08-14 Novartis Ag Composiciones para el tratamiento de infeccion de hepatitis c.
US20100122054A1 (en) * 2008-11-12 2010-05-13 Sandisk Il Ltd. Copy safe storage
AU2010333656B2 (en) * 2009-12-18 2015-08-27 Boehringer Ingelheim International Gmbh HCV combination therapy
EP2646038A1 (en) * 2010-11-30 2013-10-09 Novartis AG New treatments of hepatitis c virus infection
CN103476409A (zh) * 2011-03-31 2013-12-25 诺华股份有限公司 治疗丙肝病毒感染的阿拉泊韦

Also Published As

Publication number Publication date
RU2014116988A (ru) 2015-11-10
MX2014003753A (es) 2014-05-01
JP2014528947A (ja) 2014-10-30
EP2760461A1 (en) 2014-08-06
AU2012314517A1 (en) 2014-04-17
US20140228281A1 (en) 2014-08-14
KR20140070565A (ko) 2014-06-10
CA2850052A1 (en) 2013-04-04
US20150328280A1 (en) 2015-11-19
WO2013045460A1 (en) 2013-04-04
CN103826654A (zh) 2014-05-28

Similar Documents

Publication Publication Date Title
Flamm et al. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Decompensated Cirrhosis: Preliminary Results of a Prospective, Multicenter Study: 239
JP2014530874A5 (pt)
RU2012136824A (ru) Способы лечения вирусной инфекции гепатита с
SI2709613T1 (en) Procedures for the treatment of HCV
RU2007105354A (ru) Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv)
BR112014005617A2 (pt) tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
DK2583677T1 (da) Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon
CA2525202A1 (en) Use of alpha interferon, ribavirin, dsrna and neuraminidase inhibitors to treat avian influenza
JP2013518124A5 (pt)
HRP20171898T1 (hr) Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika
NZ631155A (en) Combination of two antivirals for treating hepatitis c
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
JP2017514911A5 (pt)
BR112014007247A2 (pt) alisporivir para o tratamento de infecção por vírus da hepatite c
RU2013129824A (ru) Новое лечение инфекции вируса гепатита с
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
BR112015010650A2 (pt) composição contendo somente levonorgestrel melhorada para contracepção oral otimizada com conteúdo definido de levonorgestrel, regime de dosagem e preparo farmacêutico
EP2606885A4 (en) "RENESSANS" MEDICINAL PREPARATION WITH ANTIBACTERIAL, ANTI-ULCER AND IMMUNOMODULATORY ACTION
RU2012109938A (ru) Способ лечения вирусного гепатита с
Jacobson et al. Characteristics of HCV-Infected Patients with Cirrhosis Requiring Ribavirin Dose Reduction During Treatment with Direct-Acting Antivirals: 1973
NZ587372A (en) Treatment of bacterial, protozoan infections and cancer with a mixture of at least three different human interferon alpha proteins
RU2013150344A (ru) Лечение инфекции вируса гепатита алисповиром
Gervasoni Emtricitabine/tenofovir disoproxil fumarate/telaprevir

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]